High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this population but rarely induce complete response (CR). Ten patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Falchi, Lorenzo, Sawas, Ahmed, Deng, Changchun, Amengual, Jennifer E., Colbourn, Donald S., Lichtenstein, Emily A., Khan, Karen A., Schwartz, Lawrence H., O’Connor, Owen A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129196/
https://ncbi.nlm.nih.gov/pubmed/27899158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0363-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados